The study of inherited predisposition to cancer is of clinical relevance, because family members at high risk may be helped by screening or by advice about prevention. It is also of biological interest, because the families offer a means to identify genes that may have important normal roles in the control of growth and differentiation, and which when faulty can predispose to malignancy.
The best known examples of inherited predisposition account for only a small proportion of cancer incidence. Early diagnosis and prophylactic surgery in the easily recognised Mendelian inherited cancer syndromes (see below) will save only perhaps 100-200 cancer deaths per year in the UK (Peto & Easton, 1991) . While this is very significant for those families, it will clearly not have much impact on the total of cancer deaths. Nevertheless, these syndromes are still important. Rare cases may be instructive in themselves; and inherited cases may have lessons for cancers in general because mutation of the same genes may be involved in the development of the inherited and the more common noninherited forms of the same cancer.
These easily recognised inherited cancers are only the tip of the iceberg (Peto, 1980; Ponder, 1990a (Peto, 1980 (Martin et al., 1990) . To move from this information to a description of the disease in terms of disordered cell biology, and from there to the wide diversity of clinical and pathological effects seen in family members (Ponder, 1990b) Mapping of the predisposing genes and development of new DNA markers will resolve some of these difficulties, but will highlight others. It may be possible with DNA markers to reassure some women who are shown not to be at risk, but this cannot be done without identifying others who have inherited the cancer gene. What of the young girl who is found to have a gene which gives her (for example) on average a 50% chance of developing breast cancer before age 60? Without an effective means of early diagnosis, this information will be hard to use for her benefit, and it may bring anxiety and problems with insurance and employment. In the long term, we can hope that finding the predisposing genes and elucidating their effects will lead to acceptable means of prevention or treatment for those at risk. More immediately, however, we need to be clear what effect the giving of genetic information has on doctors and families, and we must address the difficult problem of evaluating the benefits of family screening for these common cancers. These are questions which, if they can be tackled at all, require a concerted national approach. In the UK, the *Cancer Family Study Group may provide the basis for such an approach, and clinicians who would like more information are invited to contact the group at the address below.
In the long term, the greatest opportunity to use knowledge of inherited predisposition to reduce deaths from cancer in the population as a whole may come not from recognition of individuals at high risk in families, but from what is coming to be called 'molecular epidemiology' -the investigation of genetic polymorphisms which affect individual susceptibility to exogenous or endogenous carcinogens, mostly without causing obvious familial clusters.
Finding the predisposed individuals and the responsible genes will be difficult. Whereas the genes for familial cancers can be mapped and identified empirically by genetic linkage, in the absence of a cancer family that strategy is difficult to apply. The alternative is to select candidate predisposing genes and to test their involvement by case-control studies. There are two problems. First, we do not know enough to choose the best candidates. Second, the assays for the genes that have been chosen so far have mostly relied on a metabolic phenotype -for example, administration of a test substance and measurement of the ratios of its metabolites in a subsequent urine sample. This is cumbersome, and except in prospective studies, open to the criticism that the phenotype is modified by the disease. Recently, however, DNA-based assays for genetic variants in the genes of the cytochrome P450 superfamily have been developed which can be used in place of phenotypic assays (Gough et al., 1990) . These studies may be the prototype for those that will have the greatest impact in the next decade. 
